Combination therapy for triple-negative breast cancer disappointing

June 13, 2012 in Cancer

Combination therapy for triple-negative breast cancer disappointing

Enlarge

Lisa A. Carey, MD

(Medical Xpress) -- A recent clinical trial testing a combination therapy for basal-like (also known as triple-negative) breast cancer demonstrates that a combination of two drugs with promising preclinical results is not as effective as researchers had hoped.

“This trial tested a drug that inhibits the Epidermal growth factor receptor (EGFR) in combination with a standard therapy for Stage IV triple-negative breast cancer,” said Lisa A. Carey, MD, who led the study. Carey is the Preyer Professor of Breast Cancer Research and medical director of the UNC Breast Center. She also serves as Associate Director for Clinical Research at UNC Lineberger Comprehensive Cancer Center.

“While we were disappointed that the combination of cetuximab plus carboplatin produced responses in fewer than 20 percent of the patients, the study provides important data about how cancers can resist EGFR inhibition and provides direction for future research,” she added.

The results were published in the Journal of Clinical Oncology.

The randomized phase II trial enrolled 102 patients with Stage IV triple-negative breast cancer. Some patients received the from the beginning of the trial and others received it only if their disease continued to progress. The investigators chose EGFR inhibition triple negative breast cancer is that in laboratory studies, this kind of breast cancer is dependent on EGFR for growth.

Phase II trials are the first step in evaluating both the safety and efficacy of new drugs or new drug combinations. In for patients with cancer, new treatments are tested in addition to or in combination with the standard of care. But sometimes just watching the tumors isn’t enough. “Because we were able to do laboratory studies examining the effect of the on the patients’ tumors both before and after therapy, we gained important insight about the genetic patterns of the EGFR pathway in these tumors and their response to therapy,” Carey said.

“Triple-negative breast cancer remains difficult to treat but with each clinical trial we learn more about how these tumors work that allows us to develop smarter approaches to treatment,” she added.

Multiple research projects – including several studies conducted at the University of North Carolina at Chapel Hill – have used DNA microarray analysis to identify biologically different breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their in a more biologically-based way. In the UNC Gillings School of Global Public Health-based Carolina Breast Cancer Study, researchers found that the basal-like, or triple negative breast cancer, affects African American women far more than white women. It is likely that this plays a role in racial differences in survival.

More information: Other members of the research team included Anastasia Ivanova, PhD, Wing-Keung Chio, MS, Madlyn Ferraro, RN, Emily Burrows, MPH, Katherine A. Hoadley, PhD, and Charles M. Perou, PhD, from the University of North Carolina at Chapel Hill; P. Kelly Marcom, MD, from Duke University; Hope S. Rugo, MD, from the University of California at San Francisco; Erica L. Mayer, MD, and Eric P. Winer, MD, from the Dana-Farber Cancer Institute; Francisco J. Esteva, MD; from the University of Texas MD Anderson Cancer Center; Mothaffar F. Rimawi, MD, from Baylor University College of Medicine; Cynthia X. Ma, MD, from Washington University in St. Louis; Minetta C. Liu, MD, from Georgetown University; Anna Maria Storniolo, MD, from Indiana University; Andrew Forero-Torres, MD, from the University of Alabama, Birmingham; Antonio C. Wolff, MD, from Johns Hopkins, University; Timothy J. Hobday, MD from the Mayo Clinic; and Philip S. Bernard, PhD, from the University of Utah.

The project was funded by the UNC Breast Cancer Specialized Program of Research Excellence, funded by the National Cancer Institute and by an additional grant from the National Institutes of Health. Other funders include Bristol-Myers Squibb and Avon Partners-for-Progress. The Translational Breast Cancer Research Consortium, which collaborated on the study, is supported by the Breast Cancer Research Foundation, the Avon Foundation, and Susan G. Komen for the Cure.

Journal reference: Journal of Clinical Oncology search and more info website

Provided by University of North Carolina at Chapel Hill School of Medicine search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

New smartphone application improves colonoscopy preparation

The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...

Cancer created 19 hours ago | popularity not rated yet | comments 0

Research examines new methods for managing digestive health

Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.

Cancer created 20 hours ago | popularity not rated yet | comments 1

New colonoscope provides ground-breaking view of colon

A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...

Cancer created May 18, 2013 | popularity 5 / 5 (2) | comments 0

ASCO: combo antibody therapy effective for melanoma

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...

Cancer created May 17, 2013 | popularity not rated yet | comments 0

Risk factors ID'd for poor cutaneous cell CA outcomes

(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...

Cancer created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast


Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

Computational tool translates complex data into simplified 2-dimensional images

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...

New theory on genesis of osteoarthritis comes with successful therapy in mice

Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

Ginger compounds may be effective in treating asthma symptoms

Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...